{
  "Cluster": "0",
  "CandidateSubtype": "fetal",
  "TopGenes": [
    "KNG1",
    "APOE",
    "CYP2E1",
    "APOC3",
    "AOX1",
    "HMGCS2",
    "FGA",
    "FGG",
    "AFM",
    "ADH4",
    "COL18A1",
    "ITIH1",
    "APOA1",
    "SULT2A1",
    "AMBP",
    "ADH1A",
    "FGB",
    "VTN",
    "RARRES2",
    "CPS1"
  ],
  "ProliferationScore": "0.070 (low)",
  "StemnessScore": "0.000 (low)",
  "ImmuneScore": "0.179 (low)",
  "PrognosticScore": "0.543 (intermediate)",
  "SupportingEvidence": [
    "Dominant mature hepatocyte metabolic program (CPS1 urea cycle, HMGCS2 ketogenesis, CYP2E1/AOX1/ADH1A/ADH4 xenobiotic metabolism)",
    "Enrichment of liver-secreted plasma proteins (APOA1/APOE/APOC3, FGA/FGB/FGG, KNG1, ITIH1, AMBP, VTN, AFM)",
    "Markers align with differentiated hepatocyte identity typical of fetal-type hepatoblastoma",
    "Lack of progenitor/cholangioblastic markers (e.g., EPCAM, KRT19, AFP, DLK1) among top genes argues against embryonal/mixed components",
    "No evidence of high-proliferation/angiogenic signatures expected for macrotrabecular patterns"
  ],
  "SuggestedExperiments": [
    "IHC/IF for CPS1, HMGCS2, CYP2E1, APOA1, HNF4A to confirm hepatocyte differentiation",
    "IHC for EPCAM, KRT19, AFP, GPC3, DLK1 to exclude embryonal/mixed components",
    "Ki-67 staining to validate low proliferative fraction",
    "Functional assays: urea production, CYP2E1 activity, and ketone body output (HMGCS2) in sorted cluster-0 cells",
    "Histopathology review (H&E) for fetal morphology and absence of macrotrabecular architecture",
    "Spatial transcriptomics or RNA in situ for CPS1/HMGCS2 to localize fetal-like regions"
  ]
}